EDMONTON, Sept. 26 /CNW/ - BioMS Medical Corp. (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that
its lead drug, MBP8298, will be the subject of two poster presentations at the
22nd Congress of the European Committee for Treatment and Research in Multiple
Sclerosis (ECTRIMS) held in Madrid, Spain on September 27-30, 2006.
